← Nuvation Bio Inc.
| Annual Trend | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Revenues: | — | — | — | $0 | $7.9m | $62.9m | $169.9m | |
| Cost of collaboration and license agreements revenue | — | — | — | — | $7.1m | $8.4m | — | |
| Cost of sales | — | — | — | $0 | $0 | $856k |
$20.1m
+2246.96%
|
|
| Research and development | $32.6m | $69.0m | $87.8m | $71.3m | $99.1m | $115.1m | $128.9m | |
| Acquired in-process research and development | — | — | — | $0 | $425.1m | $0 | — | |
| Selling, general and administrative | — | — | — | $28.5m | $69.2m | $151.6m | $158.6m | |
| Total costs and expenses | $43.6m | $93.3m | $119.7m | $99.8m | $593.4m | $276.0m | $287.4m | |
| Loss from operations | ($3.1m) |
($93.3m)
-2948.16%
|
($119.7m)
-28.31%
|
($99.8m)
+16.63%
|
($592.6m)
-493.68%
|
($213.1m)
+64.05%
|
— | |
| Interest expense | — | — | — | $0 | ($341k) | ($13.7m) | $26.7m | |
| Interest income | $1.9m | $3.0m | $7.4m | $24.6m | $27.1m | $21.4m | $21.0m | |
| Realized gain (loss) on marketable securities | — | — | — | ($139k) | ($12k) | $5k | — | |
| Change in unrealized gain (loss) on available-for-sale securities | — | ($2.7m) | ($4.3m) | $5.7m | ($145k) | $741k | — | |
| Other income (expense) | — | — | — | — | ($109k) | $2.3m | ($6.6m) | |
| Total other income, net | $1.9m | $6.5m | $15.5m | $24.0m | $24.7m | $8.4m | — | |
| Loss before income taxes | ($41.7m) | ($86.8m) | ($104.2m) | ($75.8m) | ($567.9m) | ($204.6m) | — | |
| Provision for income taxes | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| Net loss on disposal of fixed assets | — | — | — | — | $0 | ($33k) | — | |
| Net loss | ($3.1m) | ($86.8m) | ($104.2m) | ($75.8m) | ($567.9m) | ($204.6m) | — | |
| Net loss per share attributable to common stockholders, basic | $0 | ($0) | ($0) | ($0) | ($2) | ($1) | — | |
| Net loss per share attributable to common stockholders, diluted | $0 | ($0) | ($0) | ($0) | ($2) | ($1) | — | |
| Weighted average common shares outstanding, basic | — | 198k | 217k | 219k | 269k | 342k | — | |
| Weighted average common shares outstanding, diluted | — | 198k | 217k | 219k | 269k | 342k | — | |
| Investment advisory fees | ($271k) | ($644k) | ($872k) | ($949k) | ($976k) | ($722k) | — | |
| Change in fair value of warrants liability | $0 | $4.2m | $10.2m | $497k | ($936k) | ($812k) | — | |
| Currency translation adjustment | — | — | — | $0 | $537k | ($1.5m) | — | |
| Comprehensive loss | ($40.5m) | ($89.6m) | ($108.5m) | ($70.1m) | ($567.5m) | ($205.4m) | — |